Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Post by ciretaka198on Jan 27, 2008 9:24pm
107 Views
Post# 14270525

patent

patent Ovasort Ltd Ovasort Ltd owns a patent on a new process for discovering proteins on the cell surface of mammalian sperm. To date the process has been used to enrich for X-chromosome bearing cells. This validates the technology both in terms of its ability to enrich specific sperm cell types on the basis of novel surface proteins and its ability to link protein discovery to specific chromosome/gene activity. This information is being used to develop a low cost sperm separation kit for sorting X- and Y-chromosome bearing cells in livestock breeding. Other applications are planned to follow. Contact: Dr Ian Cumming MRCVS, Ovasort Limited, Cardiff Medicentre, Heath Park, Cardiff CF14 4JU, Tel: 01404 831104 Email: icumming@ukf.net
Bullboard Posts